Skip to main content

The U.S. Food and Drug Administration (FDA) has denied the request by Advaxis, Inc. for orphan drug designation (ODD) for their investigative agent ADXS11-001. The request for the ODD included the indication for ADXS11-001 in the treatment of invasive cervical cancer.

The FDA stated that the prevalence of invasive cervical cancer includes all those who have been cured of the disease and thus exceeds the 200,000 person limit necessary for eligibility of ODD.

As phase I study results were promising, Advaxis, Inc may seek Fast Track designation for ADXS11-001 in the near future.

ADXS11-001 includes a Listeria monocytogenes (Lm) bacterium bioengineered to secrete two different antigen-adjuvant fusion proteins targeting cancer cells.

Scroll to Continue

Recommended Articles


Cancer’s Glamour Girl

Diagnosed with CML at 23 Erin Ruddy shares her journey.


Jonna's Body, Please Hold

Actress, playwright, and three-time cancer survivor Jonna Tamases celebrates life from center stage.


Neulasta Treatment of Neutropenia Improves Treatment

Understand the role of Neulasta treatment of Neutropenia to prevent infection and improve chemotherapy treatment.